Bill > SB252

This bill requires additional disclosure and labeling for certain products in Missouri that may have gene therapy or genetic modification capabilities. Specifically, the bill mandates that any product with potential gene therapy properties must be labeled "Potential Gene Therapy Product" and products known to be gene therapy products must be labeled "Gene Therapy Product." The legislation also requires entities producing, selling, or distributing products with the potential to infect or expose individuals to genetically modified material to provide comprehensive information upon written request from a Missouri resident within 21 days. Furthermore, the bill stipulates that any product capable of acting as a medical intervention, vaccine, drug, or causing genetic modification must obtain fully informed consent from individuals who could potentially be exposed, which includes detailed disclosure of benefits, risks, side effects, and potential adverse events. The bill defines key terms such as "gene therapy product" broadly, including any product with the capacity to alter or interfere with genes, and applies to a wide range of substances like foods, cosmetics, and medical interventions. The legislation emphasizes transparency and individual awareness about potential genetic impacts of products.

Health and Social Services

https://www.senate.mo.gov/25info/BTS_Web/Bill.aspx?SessionType=R&BillID=500